Scott Ribich

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

Antoîne Italiano, Jean‐Charles Soria, Maud Toulmonde et al. · The Lancet Oncology · 2018 · 614 citations

Medicine, Oncology, Pharmacology +12

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models

Elayne Chan-Penebre, Kristy G. Kuplast, Christina R. Majer et al. · Nature Chemical Biology · 2015 · 546 citations

Medicine, Medicinal Chemistry, Pharmacology +8

Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis

Eric E. Gardner, Benjamin H. Lok, Valentina E. Schneeberger et al. · Cancer Cell · 2017 · 535 citations · Full text

Medicine, Cancer Biology, Oncology +14

Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP

Amy K. Walker, Fajun Yang, Karen Jiang et al. · Genes & Development · 2010 · 353 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17

Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss

Andrew Fedoriw, Satyajit Rajapurkar, Shane W. O’Brien et al. · Cancer Cell · 2019 · 347 citations · Full text

Medicine, Oncology, Pharmacology +7